JACKSONVILLE, Florida, October 7, 2015 /PRNewswire/ --
TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the Aegis Capital Corp. 2015 Growth Conference, at the Encore Wynn Hotel in Las Vegas, Nevada which takes place October 7-9, 2015. The presentation will be on Friday, October 9th, 1:30-2:00 PST in Brahms 1.
Dr. John N. Bonfiglio, Board member and Strategic Advisor to TapImmune, will present an overall update and review of TapImmune's currently planned Phase ll clinical development programs in breast and ovarian cancer. Investors interested in a one-on-one meeting may contact Aegis or TapImmune directly.
Glynn Wilson, TapImmune's CEO said, "We have made significant clinical progress over the past year with the completion of Phase I clinical trials in Her2/neu breast cancer and ovarian cancer. The recent announcement of the $13.3M Phase II grant to the Mayo Clinic from the Department of Defense using our technology greatly increases our ability to progress multiple clinical programs. This conference is an ideal opportunity for TapImmune to provide an update on our entry into Phase II clinical trials."
The Aegis conference is expected to bring more than 100 presenting companies and more than 500 individuals together for three days of one-on-one meetings and various networking events. The conference serves as a platform for individuals in the healthcare, technology, telecom, and aerospace-defense sectors to network and discuss innovations in their respective fields. For more information, please visit: http://www.aegiscapcorp.com/.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Glynn Wilson, Ph.D.
Chairman & CEO
SOURCE TapImmune, Inc.